Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Trends in PRO reporting in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2019.
Authors
Houssein Safa
The University of Texas MD Anderson Cancer Center, Houston, TX
Houssein Safa, Monica Tamil, Adi Diab, Adele Semaan, Jad Chahoud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Patient-Related Outcomes
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 105)
Abstract #
105
Poster Bd #
B4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo
Poster
2020 Genitourinary Cancers Symposium
Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018.
First Author: Monica Tamil
Poster
2024 ASCO Genitourinary Cancers Symposium
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.
First Author: Elaine Chang